Literature DB >> 18767272

Evaluation of the surveillance of hemolytic uremic syndrome in British Columbia: should it remain reportable?

Kathleen Laberge1, Eleni Galanis.   

Abstract

BACKGROUND: Hemolytic Uremic Syndrome (HUS) was made reportable in British Columbia (BC) in 1998 to detect, control and prevent verotoxigenic Escherichia coli (VTEC) cases. Concerns about under-reporting of HUS cases triggered the assessment of the sensitivity and timeliness of the reporting process in order to guide recommendations around reportability of this syndrome in BC.
METHODS: The BC hospitalization database was used to estimate the total number of HUS cases from April 30, 1998 to December 31,2005. HUS and VTEC cases reported in the integrated Public Health Information System (iPHIS), and HUS cases reported by a surveillance form were linked to hospitalized cases. The proportion of HUS cases detected by each of the surveillance processes was assessed. The time interval between onset of diarrhea and reporting of HUS and VTEC cases to the BC Centre for Disease Control was compared.
RESULTS: 57 HUS cases were hospitalized. Sensitivity of reporting through the surveillance form and through iPHIS was 7.0% and 19.3%, respectively. The median time interval between onset of diarrhea and reporting of both HUS and VTEC cases to iPHIS was seven days. The median time interval for reporting HUS cases via the surveillance form was 25 days.
CONCLUSIONS: HUS cases were severely under-reported, the timeliness of reporting of these cases had no advantage when compared to the reporting of VTEC cases, and no public health action aimed at reducing the transmission of VTEC infections resulted from this surveillance system. The reportability of HUS in BC needs to be reconsidered, or its surveillance considerably improved.

Entities:  

Mesh:

Year:  2008        PMID: 18767272      PMCID: PMC6976247     

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  11 in total

Review 1.  Haemolytic uraemic syndrome: an overview.

Authors:  Iradj Amirlak; Bardia Amirlak
Journal:  Nephrology (Carlton)       Date:  2006-06       Impact factor: 2.506

2.  Updated guidelines for evaluating public health surveillance systems: recommendations from the Guidelines Working Group.

Authors:  R R German; L M Lee; J M Horan; R L Milstein; C A Pertowski; M N Waller
Journal:  MMWR Recomm Rep       Date:  2001-07-27

3.  Prospective surveillance of Canadian children with the haemolytic uraemic syndrome.

Authors:  François Proulx; Paul Sockett
Journal:  Pediatr Nephrol       Date:  2005-04-15       Impact factor: 3.714

4.  Population-based trends in pediatric hemolytic uremic syndrome in California, 1994-1999: substantial underreporting and public health implications.

Authors:  Kate C Cummings; Janet C Mohle-Boetani; S Benson Werner; Duc J Vugia
Journal:  Am J Epidemiol       Date:  2002-05-15       Impact factor: 4.897

Review 5.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  Haemolytic uraemic syndrome and Shiga toxin-producing Escherichia coli infection in children in France. The Société de Néphrologie Pédiatrique.

Authors:  B Decludt; P Bouvet; P Mariani-Kurkdjian; F Grimont; P A Grimont; B Hubert; C Loirat
Journal:  Epidemiol Infect       Date:  2000-04       Impact factor: 2.451

7.  Hemolytic-Uremic Syndrome and Escherichia coli O121 at a Lake in Connecticut, 1999.

Authors:  T A McCarthy; N L Barrett; J L Hadler; B Salsbury; R T Howard; D W Dingman; C D Brinkman; W F Bibb; M L Cartter
Journal:  Pediatrics       Date:  2001-10       Impact factor: 7.124

Review 8.  Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression.

Authors:  Amit X Garg; Rita S Suri; Nick Barrowman; Faisal Rehman; Doug Matsell; M Patricia Rosas-Arellano; Marina Salvadori; R Brian Haynes; William F Clark
Journal:  JAMA       Date:  2003-09-10       Impact factor: 56.272

9.  Hemolytic uremic syndrome risk and Escherichia coli O157:H7.

Authors:  Boldtsetseg Tserenpuntsag; Hwa-Gan Chang; Perry F Smith; Dale L Morse
Journal:  Emerg Infect Dis       Date:  2005-12       Impact factor: 6.883

10.  Hemolytic uremic syndrome incidence in New York.

Authors:  Hwa-Gan H Chang; Boldtsetseg Tserenpuntsag; Marilyn Kacica; Perry F Smith; Dale L Morse
Journal:  Emerg Infect Dis       Date:  2004-05       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.